Is insulin the most effective injectable antihyperglycaemic therapy?

Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M

Diabetes, obesity & metabolism9 Nov 2014Cited by 24 (Europe PMC)

PMID25323312DOI10.1111/dom.12402PepBankPUB-25323312

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c reduction with pooled GLP-1 receptor agonists (exenatide once weekly, liraglutide) was similar or numerically greater than with glargine in all baseline HbA1c quartiles at 26 weeks.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered HbA1c about as much as or more than glargine insulin at 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction by baseline HbA1c quartile
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At 26 weeks, in both studies, HbA1c reduction, and proportion of subjects reaching HbA1c <7.0%, were similar or numerically greater with the GLP-1RAs than glargine
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2532331201
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the proportion reaching HbA1c below 7.0% with pooled GLP-1 receptor agonists was similar or numerically greater than with glargine in all quartiles.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group got as many or more people to the HbA1c target as glargine insulin.
Peptide
Liraglutide
Outcome
No significant changeProportion reaching HbA1c <7.0% by baseline quartile
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At 26 weeks, in both studies, HbA1c reduction, and proportion of subjects reaching HbA1c <7.0%, were similar or numerically greater with the GLP-1RAs than glargine for all baseline HbA1c quartiles.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2532331202
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting glucose reduction was similar or numerically greater with glargine than with pooled GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, glargine insulin lowered fasting blood sugar as much as or more than GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose reduction
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Fasting glucose reduction was similar or numerically greater with glargine.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2532331203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight decreased with both pooled GLP-1 receptor agonists across all quartiles, while subjects taking glargine gained weight.
In plain wordsIn adults with type 2 diabetes, weight fell with GLP-1 drugs as a group, while people on glargine insulin gained weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight decreased with both GLP-1RAs across all quartiles; subjects taking glargine gained weight, more at higher baseline HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2532331204
05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, gastrointestinal events occurred more frequently with pooled GLP-1 receptor agonists than with glargine.
In plain wordsIn adults with type 2 diabetes, stomach and gut side effects were more common with GLP-1 drugs as a group than with glargine insulin.
Peptide
Liraglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Adverse events were uncommon although gastrointestinal events occurred more frequently with GLP-1RAs.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2532331205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00331851

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 584May 2006 to Apr 2007

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.